US Patent Issued to Genentech on July 21 for "Methods for treatment of B cell proliferative disorders with anti-CD20/anti-CD3 bispecific antibodies" (California Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,715, issued on July 21, was assigned to Genentech Inc. (South San Francisco, Calif.).

"Methods for treatment of B cell proliferative disorders with anti-CD20/anti-CD3 bispecific antibodies" was invented by Chi-Chung Li (South San Francisco, Calif.), Carol Elaine O'Hear (South San Francisco, Calif.) and Xi Chen (South San Francisco, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the treatment of subjects having B cell proliferative disorders, including high grade B-cell lymphomas, as well as non-Hodgkin's lymphomas, such as diffuse large B-cell lymphomas. More specifically, the invention pertains to the treatme...